Carlos Iii Health Institute

Novel CAR-T Cell Therapy Shows 100% Response Rate in Refractory CD30+ Lymphoma Patients

25 days ago

• A groundbreaking CAR-T cell therapy targeting CD30 protein (HSP-CAR30) has achieved a 100% overall response rate in patients with refractory CD30+ lymphoma, with 50% achieving complete remission. • The Phase I clinical trial demonstrated remarkable durability, with 60% of complete responders remaining in remission after a median follow-up of 34 months, and CAR30+ cells persisting in 60% of evaluable patients one year post-infusion. • Developed by researchers at Sant Pau Research Institute in collaboration with Sant Pau Hospital and Josep Carreras Leukaemia Research Institute, this first successful European CAR-T30 study offers new hope for patients with limited treatment options.

IMPaCT 'Digital Twins' Project Creates Virtual Cancer Models for Personalized Treatment

7 months ago

• The IMPaCT 'Digital Twins' project has enrolled 110 women with advanced breast, lung, or colon cancer to create virtual models of their diseases. • These digital twins, powered by AI, aim to predict disease evolution and identify optimal treatments and lifestyle habits for individual patients. • The project, a personalized medicine initiative led by CNIO, utilizes patient data from smartwatches, apps, and biological samples. • Initial data from 30 participants were presented at ESMO, demonstrating high sample quality and active patient collaboration.